Placental site trophoblastic tumor is a rare sub-group of gestational trophoblastic neoplasia. There is a wide clinical spectrum of presentation and behaviour ranging from a benign condition to an aggressive disease w...Placental site trophoblastic tumor is a rare sub-group of gestational trophoblastic neoplasia. There is a wide clinical spectrum of presentation and behaviour ranging from a benign condition to an aggressive disease with a fatal outcome. We report a case of placental site trophoblastic tumor in 23-year-old women with irregular vaginal bleeding during postpartum lactation period. In addition to persistent low level β-hCG titers, ultrasound examination revealed a suspicious low-echoic area in the myometrium consistent with gestational trophoblastic disease. After histopathological examination of the specimen achieved by ultrasound-guided dilatation and curettage of the uterus, the placental site trophoblastic tumor diagnosis was made and subsequently total abdominal hysterectomy was performed. The patient had an uneventful recovery, and no recurrence was detected for 40 months in the follow-up period.展开更多
Gestational trophoblastic neoplasia(GTN) is a rare tumor that originates from pregnancy that includes invasive mole, choriocarcinoma(CCA), placental site trophoblastic tumor and epithelioid trophoblastic tumor(PSTT/ET...Gestational trophoblastic neoplasia(GTN) is a rare tumor that originates from pregnancy that includes invasive mole, choriocarcinoma(CCA), placental site trophoblastic tumor and epithelioid trophoblastic tumor(PSTT/ETT). GTN presents different degrees of proliferation, invasion and dissemination, but, if treated in reference centers, has high cure rates, even in multi-metastatic cases.The diagnosis of GTN following a hydatidiform molar pregnancy is made according to the International Federation of Gynecology and Obstetrics(FIGO)2000 criteria: four or more plateaued human chorionic gonadotropin(hCG)concentrations over three weeks; rise in hCG for three consecutive weekly measurements over at least a period of 2 weeks or more; and an elevated but falling hCG concentrations six or more months after molar evacuation. However,the latter reason for treatment is no longer used by many centers. In addition,GTN is diagnosed with a pathological diagnosis of CCA or PSTT/ETT. For staging after a molar pregnancy, FIGO recommends pelvic-transvaginal Doppler ultrasound and chest X-ray. In cases of pulmonary metastases with more than 1cm, the screening should be complemented with chest computed tomography and brain magnetic resonance image. Single agent chemotherapy, usually Methotrexate(MTX) or Actinomycin-D(Act-D), can cure about 70% of patients with FIGO/World Health Organization(WHO) prognosis risk score ≤ 6(low risk), reserving multiple agent chemotherapy, such as EMA/CO(Etoposide,MTX, Act-D, Cyclophosphamide and Oncovin) for cases with FIGO/WHO prognosis risk score ≥ 7(high risk) that is often metastatic. Best overall cure rates for low and high risk disease is close to 100% and > 95%, respectively. The management of PSTT/ETT differs and cure rates tend to be a bit lower. The early diagnosis of this disease and the appropriate treatment avoid maternal death,allow the healing and maintenance of the reproductive potential of these women.展开更多
目的探讨胎盘部位结节(placental site nodules,PSNs)的临床表现与组织学特征及临床意义。方法收集20例PSNs,分析其临床表现、超声检测、组织学形态及免疫表型特征。结果患者年龄25~41岁,平均(32.48±4.77)岁,有3/5的患者有2次及以...目的探讨胎盘部位结节(placental site nodules,PSNs)的临床表现与组织学特征及临床意义。方法收集20例PSNs,分析其临床表现、超声检测、组织学形态及免疫表型特征。结果患者年龄25~41岁,平均(32.48±4.77)岁,有3/5的患者有2次及以上妊娠史,诊断为PSNs时距上次妊娠间隔5~37个月,平均(15.33±8.05)个月,15例(75%)患者因阴道不规则出血就诊。大体上PSNs大多呈膜样结构,未见明确的结节;镜下可见内膜组织中1个或多个边界清楚的卵圆形结节,结节中央为玻璃样变,周边可见数量不等的中间型滋养细胞。免疫表型:CK(AE1/AE3)、CAM5.2、EMA、GATA-3、Cyclin E、p63强阳性,PLAP局限性强阳性,α-inhibin、h PL微弱且局限性阳性,Ki-67增殖指数1%~4%。结论 PSNs是源于绒毛膜中间型滋养细胞的良性非肿瘤性病变,需与透明样变的蜕膜组织、上皮样滋养细胞肿瘤及透明样变的鳞状细胞癌等鉴别,必要时可借助于免疫组化辅助诊断。展开更多
目的探讨血β-hCG在胎盘部位滋养细胞肿瘤(placental site trophoblastic tumors,PSTT)中的特点及其在诊断,疗效评价,病情监测中的价值。方法对1999年6月至2011年1月北京协和医院收治的40例PSTT患者的血β-hCG和临床资料进行回顾性分析...目的探讨血β-hCG在胎盘部位滋养细胞肿瘤(placental site trophoblastic tumors,PSTT)中的特点及其在诊断,疗效评价,病情监测中的价值。方法对1999年6月至2011年1月北京协和医院收治的40例PSTT患者的血β-hCG和临床资料进行回顾性分析。结果病程中最高血β-hCG0.5～8194mIU/ml,平均(1593.2±2330.7)mIU/ml;发病时血β-hCG≤1000mIU/ml28例(28/34,82.35%),病程中最高血β-hCG≤1000mIU/ml23例(23/34,67.65%);14例(14/22,63.64%)在术前化疗2个疗程后血β-hCG未下降50%;29例获得完全缓解者术前血β-hCG0.5～332.6mIU/ml,平均(75.4±97.2)mIU/ml,术后0～82.9mIU/ml,平均(6.3±15.5)mIU/ml,术后<10mIU/ml者共25例,占86.21%;7例结局不良者术前血β-hCG495～4785mIU/ml,平均1620.7mIU/ml,术后35.95～584.6mIU/ml,平均233.8mIU/ml。结论 PSTT病变的严重程度与血β-hCG的水平不成正比,血β-hCG可作为PSTT诊断的线索,疗效评价、病情监测的指标,手术前后血β-hCG变化可以一定程度预测PSTT预后。展开更多
目的探讨细胞核因子-κBp65(NF-κBp65)、CD44v6、Kiss-1在胎盘部位滋养细胞肿瘤中的表达及相关性。方法采用免疫组化PV 6000两步法检测20例正常早孕绒毛、15例葡萄胎、15例绒癌、10例胎盘部位滋养细胞肿瘤(placent site tropho-blastic...目的探讨细胞核因子-κBp65(NF-κBp65)、CD44v6、Kiss-1在胎盘部位滋养细胞肿瘤中的表达及相关性。方法采用免疫组化PV 6000两步法检测20例正常早孕绒毛、15例葡萄胎、15例绒癌、10例胎盘部位滋养细胞肿瘤(placent site tropho-blastic tumor,PSTT)中NF-κBp65、CD44v6、Kiss-1的表达情况及相关性。结果 NF-κBp65、CD44v6分别在正常早孕绒毛、葡萄胎、PSTT、绒癌中表达呈升高趋势,差异有统计学意义(P1<0.01、P2<0.01)。NF-κBp65、CD44v6在PSTT中表达高于正常早孕绒毛和葡萄胎中的表达,差异有统计学意义(P1<0.01、P2<0.01、P3<0.01、P4<0.05);NF-κBp65在PSTT和绒癌中表达差异有统计学意义(P<0.01);CD44v6在PSTT和绒癌中表达差异无统计学意义(P>0.05)。Kiss-1在正常早孕绒毛、葡萄胎、PSTT、绒癌中表达呈下降趋势,差异有统计学意义(P<0.01)。Kiss-1在PSTT中表达低于正常早孕绒毛和葡萄胎中的表达,差异有统计学意义(P1<0.01,P2<0.01);在PSTT和绒癌中表达差异无统计学意义(P>0.05)。NF-κBp65和CD44v6呈正相关(r=0.356,P=0.005)和Kiss-1呈负相关(r=-0.527,P=0.000);CD44v6和Kiss-1呈负相关(r=-0.346,P=0.007)。结论 NF-κBp65、CD44v6的高表达和Kiss-1的低表达可能在胎盘部位滋养细胞肿瘤的浸润转移中起重要作用。展开更多
文摘Placental site trophoblastic tumor is a rare sub-group of gestational trophoblastic neoplasia. There is a wide clinical spectrum of presentation and behaviour ranging from a benign condition to an aggressive disease with a fatal outcome. We report a case of placental site trophoblastic tumor in 23-year-old women with irregular vaginal bleeding during postpartum lactation period. In addition to persistent low level β-hCG titers, ultrasound examination revealed a suspicious low-echoic area in the myometrium consistent with gestational trophoblastic disease. After histopathological examination of the specimen achieved by ultrasound-guided dilatation and curettage of the uterus, the placental site trophoblastic tumor diagnosis was made and subsequently total abdominal hysterectomy was performed. The patient had an uneventful recovery, and no recurrence was detected for 40 months in the follow-up period.
文摘Gestational trophoblastic neoplasia(GTN) is a rare tumor that originates from pregnancy that includes invasive mole, choriocarcinoma(CCA), placental site trophoblastic tumor and epithelioid trophoblastic tumor(PSTT/ETT). GTN presents different degrees of proliferation, invasion and dissemination, but, if treated in reference centers, has high cure rates, even in multi-metastatic cases.The diagnosis of GTN following a hydatidiform molar pregnancy is made according to the International Federation of Gynecology and Obstetrics(FIGO)2000 criteria: four or more plateaued human chorionic gonadotropin(hCG)concentrations over three weeks; rise in hCG for three consecutive weekly measurements over at least a period of 2 weeks or more; and an elevated but falling hCG concentrations six or more months after molar evacuation. However,the latter reason for treatment is no longer used by many centers. In addition,GTN is diagnosed with a pathological diagnosis of CCA or PSTT/ETT. For staging after a molar pregnancy, FIGO recommends pelvic-transvaginal Doppler ultrasound and chest X-ray. In cases of pulmonary metastases with more than 1cm, the screening should be complemented with chest computed tomography and brain magnetic resonance image. Single agent chemotherapy, usually Methotrexate(MTX) or Actinomycin-D(Act-D), can cure about 70% of patients with FIGO/World Health Organization(WHO) prognosis risk score ≤ 6(low risk), reserving multiple agent chemotherapy, such as EMA/CO(Etoposide,MTX, Act-D, Cyclophosphamide and Oncovin) for cases with FIGO/WHO prognosis risk score ≥ 7(high risk) that is often metastatic. Best overall cure rates for low and high risk disease is close to 100% and > 95%, respectively. The management of PSTT/ETT differs and cure rates tend to be a bit lower. The early diagnosis of this disease and the appropriate treatment avoid maternal death,allow the healing and maintenance of the reproductive potential of these women.
文摘目的探讨血β-hCG在胎盘部位滋养细胞肿瘤(placental site trophoblastic tumors,PSTT)中的特点及其在诊断,疗效评价,病情监测中的价值。方法对1999年6月至2011年1月北京协和医院收治的40例PSTT患者的血β-hCG和临床资料进行回顾性分析。结果病程中最高血β-hCG0.5～8194mIU/ml,平均(1593.2±2330.7)mIU/ml;发病时血β-hCG≤1000mIU/ml28例(28/34,82.35%),病程中最高血β-hCG≤1000mIU/ml23例(23/34,67.65%);14例(14/22,63.64%)在术前化疗2个疗程后血β-hCG未下降50%;29例获得完全缓解者术前血β-hCG0.5～332.6mIU/ml,平均(75.4±97.2)mIU/ml,术后0～82.9mIU/ml,平均(6.3±15.5)mIU/ml,术后<10mIU/ml者共25例,占86.21%;7例结局不良者术前血β-hCG495～4785mIU/ml,平均1620.7mIU/ml,术后35.95～584.6mIU/ml,平均233.8mIU/ml。结论 PSTT病变的严重程度与血β-hCG的水平不成正比,血β-hCG可作为PSTT诊断的线索,疗效评价、病情监测的指标,手术前后血β-hCG变化可以一定程度预测PSTT预后。
